focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.575
Bid: 17.85
Ask: 19.45
Change: 0.00 (0.00%)
Spread: 1.60 (8.964%)
Open: 18.575
High: 0.00
Low: 0.00
Prev. Close: 18.575
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of mobile agri-waste treatment solution

7 Mar 2017 07:00

RNS Number : 6790Y
BATM Advanced Communications Ld
07 March 2017
 

7 March 2017

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

BATM launches World's first Mobile Agri-Waste Solution and Wins $2.5m Contract

 

BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce that its Pathogenic Waste Treatment and Sterilisation unit has launched the world's first mobile agri-waste treatment solution and has been awarded a contract worth $2.5m. BATM has received an advance payment of $1m with delivery of the product expected to commence during H2 2017 and due to complete in Q1 2018.

 

The contract is for the delivery of a mobile unit giving the customer the ability to deploy the solution for the safe disposal of mass poultry affected by disease and illness. Poultry affected by disease and illness cannot be transported from their location and are disposed of on-site either via burning or burial. The treatment process is completely eco-friendly with no hazardous materials or chemicals used and creates no odour.

 

This order follows the successful installation and operation over the last several months of an agri-waste treatment solution at a major rendering site. BATM received two significant orders for stationary units, one for treating poultry and another contract to treat bovine remains. Both contracts are advancing well with full commercial deployment of the first one expected in H1 2017.

 

BATM's agri-waste treatment solutions utilise the Group's proprietary medical sterilisation solution ("ISS") in the rendering process, allowing the safe treatment of animal remains to generate valuable protein and fat. These proteins and fats can be used for animal or fish food and provide an additional source of revenue for the Group's customers.

 

Dr. Zvi Marom, CEO of BATM, said: "We are very pleased to have received this significant order for our mobile agri-waste treatment solution from such a major customer. Our agri-waste solution is unique and, in addition to its cost advantages and savings, provides a perfect ecological solution. We believe that making our solution mobile presents our customers with a new, efficient and eco-friendly way of dealing with animal diseases.

 

"Our ISS technology has become the leading biologic and pathogenic waste solution in the medical market and is now deployed by more than 400 hospitals. As demonstrated by our agri-waste solutions, we are finding new applications for this technology on a much larger scale in both the biopharma and agricultural fields. Our ISS solution recently received a patent in the US and we expect our agri-waste solution to do the same in due course.

 

"BATM management expects to receive more orders based on the ISS technology this year."

 

 

Enquiries:

 

BATM Advanced Communications

 

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

 

 

 

finnCap

 

Stuart Andrews, Scott Mathieson

+44 20 7220 0500

 

 

Shore Capital

 

Mark Percy, Anita Ghanekar

+44 20 7408 4050 

 

 

Luther Pendragon

 

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLFFELVFIRIID
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.